<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>2-Chlorodeoxyadenosine (cladribine, Leustatin) is being used extensively in the treatment of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, but relatively little is known regarding its toxicity to the <z:mpath ids='MPATH_458'>normal</z:mpath> marrow </plain></SENT>
<SENT sid="1" pm="."><plain>Long-term serial hematologic observations have been made on 29 patients with multiple <z:mp ids='MP_0000612'>sclerosis</z:mp> undergoing experimental therapy with monthly courses of cladribine, each of which consisted of 0.087-0.1 mg/kg per day for 7 days </plain></SENT>
<SENT sid="2" pm="."><plain>The characteristic hematologic responses of the patients consisted of <z:hpo ids='HP_0011009'>acute</z:hpo> transient <z:mp ids='MP_0000223'>monocytopenia</z:mp>, prolonged, profound <z:hpo ids='HP_0001888'>lymphopenia</z:hpo> especially of CD4-positive cells, and modest lowering of the granulocyte count and <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> with development of long-lasting <z:mp ids='MP_0000248'>macrocytosis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Two patients developed severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, requiring transfusion both of red cells and platelets </plain></SENT>
<SENT sid="4" pm="."><plain>One of these had previously received extensive therapy with <z:chebi fb="5" ids="28830">chlorambucil</z:chebi>, while the other had received carbamazepine (<z:chebi fb="0" ids="8502">Tegretol</z:chebi>) and was ingesting phenytoin (Dilantin) at the time of cladribine therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Both patients recovered after several months of marrow suppression </plain></SENT>
</text></document>